[Experimental studies on intermittent use of rifampicin alone or combined with other secondary antituberculous drugs].
D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000995:Antitubercular Agents / Q000008:administration & dosage*; D001835:Body Weight; D004977:Ethambutol / Q000008:administration & dosage; D005000:Ethionamide / Q000008:administration & dosage; D007273:Injections, Intramuscular; D007612:Kanamycin / Q000008:administration & dosage; D008168:Lung; D051379:Mice; D009929:Organ Size; D011718:Pyrazinamide / Q000008:administration & dosage; D012293:Rifampin / Q000008:administration & dosage*; D013154:Spleen; D014376:Tuberculosis / Q000188:drug therapy*; D014756:Viomycin / Q000008:administration & dosage
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D011718:Pyrazinamide; D007612:Kanamycin; D004977:Ethambutol; D005000:Ethionamide; D012293:Rifampin; D014756:Viomycin